All these results further validated the inhibitory effects of Bazedoxifene on GP130 mediated STAT3 activation, suggesting the ability of Bazedoxifene to block IL-6/GP130/STAT3 signaling in rhabdomyosarcoma cells. Here, STAT3 is linked to rhabdomyosarcoma.